PARIS, France, February 2nd, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative
Pharnext announces successful completion of manufacturing transfer and scale - up of PXT3003 in the United States
PARIS, France, January 26th, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA)
Pharnext supports and participates in the 21st King's College Symposium on Neuromuscular Disease s in London
PARIS, France, January 25th, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the
PARIS, France, January 24, 2023 at 8:30 a.m. (CET) - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases
PARIS, France, January 19th, 2023, at 8h30 (CET) - Néovacs (FR00140077X1 - ALNEV), a French biotech company specializing in therapeutic vaccines for the treatment of autoimmune diseases